Meta-analysis confirms rasagiline efficacy in Parkinson's disease
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Rasagiline (Azilect), a selective inhibitor of monoamine oxidase B, reduces a variety of symptoms of Parkinson's disease.
Why this matters
Individual trials of rasagiline for Parkinson's disease have generally been small.
Relative to peers given placebo, patients given rasagiline at either 1 or 2 mg/d had greater improvements in Unified Parkinson's Disease Rating Scale (UPDRS) total scores (difference in means, 3.305 [P<.001] and 3.287 [P<.001]).
Patients given the 1 mg/d dose also had greater improvements in UPDRS Part I (mentation) scores (difference in means, 0.237; P<.001).
Both the 1 and 2 mg/d rasagiline groups had greater improvements in UPDRS Part II (activity of daily living) scores (difference in means, 0.909 [P<.001] and 0.979 [P<.001]) and Part III (motor) scores (difference in means, 2.044 [P<.001] and 2.043 [P<.001]).
Improved UPDRS total scores were seen whether rasagiline was used alone or co...